While an estimated 83 percent of new mothers in the United States breastfeed at some time during the postpartum period, and more than half of women breastfeeding take one or more medications, most clinical studies exclude lactating women so the effects of those medications on mom and baby aren’t directly known.
A New England Journal of Medicine report penned by scientists at Harvard Med and Google offers a blueprint for integrating machine learning into the practice of medicine as way to optimize clinical care.
Hospitals that perform the highest volume of transcatheter-aortic valve replacement (TAVR) procedures have significantly lower mortality rates than centers that do fewer of the minimally invasive surgeries.
Due to advances in treatment, an ever-increasing number of patients are living longer as metastatic cancer survivors. They and their doctors face a host of new challenges that require immediate attention.
The Valley Hospital participated in a landmark clinical trial that evaluated the ability of a novel, fully absorbable antibacterial envelope – the Medtronic TYRX™ Absorbable Antibacterial Envelope – to reduce infections associated with cardiac implantable electronic devices (CIEDs). The study found positive results and demonstrated that the envelope reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, in patients at increased risk for infections receiving CIEDs, compared to standard-of-care pre-operative antibiotics.
Stanley Chetcuti, M.D., co-author on the Evolut trial of low-risk TAVR/ interventional cardiologist at Michigan Medicine (University of Michigan) comments on importance of both late-breaking clinical trials re: low-risk TAVR (Evolut and Partner 3) at the American College of Cardiology Scientific Sessions.
A new study by a team of cardiologists at Beth Israel Deaconess Medical Center (BIDMC) led by senior and corresponding author Jeffrey Popma, MD, suggests that a minimally invasive procedure currently reserved for patients too frail to undergo surgery may in fact be a safe and effective alternative for healthier patients.
A Cleveland Clinic-led research team has found that using an absorbable, antibiotic-eluting envelope when implanting cardiac devices like pacemakers and defibrillators can cut the rate of major infections by 40 percent. The research was presented today at the American College of Cardiology’s 68th Annual Scientific Session and simultaneously published in the New England Journal of Medicine. It will also be presented tomorrow at the European Heart Rhythm Association 2019 Congress.
S. Chris Malaisrie, MD, a cardiac surgeon at Northwestern Memorial Hospital, associate professor of surgery (cardiac surgery) at Northwestern University Feinberg School of Medicine and co-chair of the PARTNER 3 case review board, is available to comment on PARTNER 3.
Analysis shows the monthly rate of first-time opioid prescriptions dropped by more than half between 2012 and 2017. Though some physicians wrote no new prescriptions at all, others continued to prescribe dosages and durations that put patients at risk for misuse, overdose and death. Findings underscore importance of nuanced, individualized prescribing over all-or-nothing approach.
Two large national studies show that patient safety was unaffected and residents showed no signs of chronic sleep loss regardless of shift length.
The Clinical Research Forum recognized the Cedars-Sinai's Smidt Heart Institute with a 2019 Top Ten Clinical Research Achievement Award today for its study aimed at developing a blood pressure control program for African-American men in the comfortable and convenient environments of their barbershops. In just six short months, the study improved the outcomes and control of high blood pressure in more than 60 percent of participants.
A clinical trial at NewYork-Presbyterian/Columbia and other centers found that patients responded to a new “smart drug” for women with an aggressive form of breast cancer.
The first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk published today in the New England Journal of Medicine. The study found no significant reduction in venous thromboembolism or death in the overall 180-day trial period; however, the researchers did observe a lower incidence of these events while patients were actively on the study drug, or during the on-treatment period.
Thousands of Americans die each year during a dangerous two-minute procedure to insert a breathing tube. Now a Vanderbilt University Medical Center (VUMC) study in the New England Journal of Medicine (NEJM) is showing that using bag-mask ventilation, squeezing air from a bag into the mouth for 60 seconds to help patients’ breathing, improves outcomes and could potentially save lives.
A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
Project CLEAR clinical trial finds that the application of antiseptic soap, mouthwash, and nose ointments prevent post-discharge MRSA infections and hospitalizations. Patients
Hospital patients who have methicillin-resistant Staphylococcus aureus (MRSA) can prevent future MRSA infections by following a standard bathing protocol after discharge, according to research results published in the February 14 issue of the New England Journal of Medicine.
Over a year and a half after the successful separation of two infant twins joined at the top of their heads, surgical team leaders report on this dramatic case. The surgeons describe the innovative devices, elaborate planning and precisely orchestrated teamwork needed to perform the complex separation surgery.
When patients fail to take prescribed medications—or don't use them the right way—they risk return trips to the hospital and cost the U.S. healthcare system more than $100 billion a year. Older hospital patients are most susceptible to drug-related problems that can lead to readmissions or even death. To help these individuals get the right medications and take them correctly after discharge, Cedars-Sinai has embedded pharmacists in the care teams treating certain high-risk patients. Medication lists are double-checked by a pharmacist for errors prior to discharge, and patients are sent home with their prescription drugs after being counseled on how to take them properly.
A landmark study has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL). The drug, ibrutinib, attacks cancer cells without damaging normal cells, thus causing fewer side effects.
Suicides and drug overdoses kill American adults at twice the rate today as they did just 17 years ago, and opioids are a key contributor to that rise, according to a new review and analysis. Reversing this deadly double trend will take investment in programs that have been proven to prevent and treat opioid addiction, the researchers say.
DNA sequencing can be used to identify the underlying genetic cause of many rare types of chronic kidney disease, leading to better treatment, finds a new study from Columbia University.
About 80 percent of patients with desmoid tumors had no progression of their tumors over a two-year period while taking a drug called sorafenib during a phase 3 clinical trial.
America lost 20,360 children and teens in 2016 -- 60 percent of them to preventable injuries, a new study shows. But while death rates from the top cause – motor vehicle crashes – have declined steadily since 1999, rates from the second-leading cause - firearms - have gone up. It’s the first time all causes of child and adolescent death have been tallied by both mechanism and intent.
By age 12 to 18 months, 6.25% of children exposed to Zika during their mothers’ pregnancies had eye abnormalities, 12.2% had hearing problems, and 11.7% had severe delays in language, motor skills and/or cognitive function. In all, 14.5% had at least one of the three abnormalities.
In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)—found that 52% of patients responded favorably to the therapy; 40% had a complete response and 12% had a partial response. One year later, 65% of those patients were relapse-free, including 79% of complete responders. The median progression-free survival “has not been reached.”
A daily hydroxyurea pill may bring relief for children living with the painful and deadly blood disease sickle cell anemia (SCA) in resource-challenged sub-Saharan Africa, where the disease is prevalent and health care is suboptimal. This is what a multinational clinical trial called REACH discovered when it tested daily hydroxyurea treatment in 606 children between the ages of 1 and 10 years old. Study data are published in the New England Journal of Medicine.
Children who enter elementary school younger than their peers are more likely to be diagnosed with ADHD. Children born in August in states with a Sept. 1 cutoff birth date for school enrollment have a 30 percent higher risk for ADHD diagnosis than peers born in September, which may reflect over-diagnosis.
A major U.S. study led by Washington University School of Medicine in St. Louis found that a commonly used probiotic is not effective in improving symptoms of diarrhea and vomiting in young children with gastroenteritis.
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.
About a year after receiving daily oral immunotherapy for severe peanut allergy, 67 percent of children in a Phase 3 trial were able to tolerate eating at least two peanuts (600 mg) without an allergic reaction, while 50 percent tolerated eating three to four peanuts (1,000 mg) without symptoms. At the start of the study, all of these children had allergic reactions after ingesting just 1/10 of a peanut (30 mg). These results of an international, randomized, double-blind, placebo-controlled trial conducted at 66 sites, including Ann & Robert H. Lurie Children’s Hospital of Chicago, were published in the New England Journal of Medicine.
Controlled ingestion of peanut protein could help build tolerance in peanut allergy sufferers. Authors of a new study published in the New England Journal of Medicine say an oral immunotherapy drug they tested could be the first FDA-approved medication of its kind for people with peanut allergy. The medication, called AR101, is derived from peanut protein.
It’s a common scenario in many emergency rooms: A man with a long history of homelessness and schizophrenia reports hallucinations and thoughts of suicide. Should the medical team admit him for hospitalization or treat him with antipsychotic drugs and release him from the ER? Lessons learned from this experience are the focus of the first article in a series of case studies that begins Nov. 15 in the New England Journal of Medicine.
Final research results for a new treatment for protection against accidental exposure to peanut were presented today at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting and published in the New England Journal of Medicine.
Scientists have found that a single-dose of the oral antibiotic zoliflodacin successfully treated uncomplicated genital infections caused by gonorrhea, according to research published in The New England Journal of Medicine.
Researchers from Case Western Reserve University School of Medicine have shown that a single “cocktail” of three pill-based anti-parasite medications is significantly more effective at killing microscopic larval worms in people diagnosed with lymphatic filariasis, commonly known as elephantiasis, than other standard two-drug combinations previously used in the global effort to eliminate this infectious disease. A combination of all three drugs given simultaneously had never been tested until now. An estimated 120 million people in over 50 tropical and subtropical countries are infected with lymphatic filariasis and another 856 million people are at risk.
By combining the experimental anti-cancer antibody known as 5F9 with the anti-cancer antibody rituximab, researchers managing a phase 1b clinical trial were able to induce a positive response in 11 out of 22 people with relapsed/refractory non-Hodgkin’s lymphoma. Eight of the 22 patients went into complete remission from their cancers.
Penn Medicine emergency department physicians are calling for more readily available testing strips to identify the presence of fentanyl in patients experiencing a drug overdose, and a rapid, coordinated response among health care providers and city agencies to help curb overdoses and identify high potency high risk drugs.
A new study found that women with cervical cancer who had a radical hysterectomy with minimally invasive surgery had a significantly higher risk of death than those who had open surgery.
When comparing standard-of-care surgical options for women with early-stage cervical cancer, two studies led by researchers at The University of Texas MD Anderson Cancer Center discovered that minimally invasive radical hysterectomy is associated with higher recurrence rates and worse overall survival (OS), compared to abdominal radical hysterectomy.
A study from Washington University School of Medicine in St. Louis offers a potential explanation for why many AML patients experience a relapse after a stem cell transplant, and suggests a therapeutic approach that may help to place relapsed patients back into remission.
Critically ill patients are not benefitting from antipsychotic medications that have been used to treat delirium in intensive care units (ICUs) for more than four decades, according to a study released today in the New England Journal of Medicine.
Progression free survival in triple-negative breast cancer increased when immunotherapy-chemotherapy treatment combination is used as the first treatment option.
An emerging treatment known as adoptive T-cell therapy has proven effective in a Phase II clinical trial for treating progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection sometimes observed in patients with cancer and other diseases in which the immune system is compromised. The study, led by Katy Rezvani, M.D., Ph.D., professor, Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center, showed marked improvement in three PML patients infused with donor T cells targeting the BK virus. Findings were published in the Oct. 11 online issue of the New England Journal of Medicine.
A new nationwide study has found that a tiny clip placed in the heart to fix a leaky mitral valve drastically decreases the risk of both dying and returning to the hospital for heart failure patients.
Penn Medicine experts in nephrology and health policy call for more transparency about joint-venture ownership of dialysis clinics to better understand what impact these arrangements may have on patient referrals and clinical outcomes. The lack of transparency poses a major barrier for evidence-based health care policy research and deprives patients of critical information, the researchers write in a new Perspective published in the New England Journal of Medicine.
Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center. New clinical trial data published this week in The New England Journal of Medicine show durvalumab improved progression-free survival by 17.2 months compared to placebo.
Results of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right